StockVS

Tilray Brands, Inc. (TLRY) स्टॉक विश्लेषण

स्वास्थ्य सेवा

Tilray Brands, Inc.

$5.45

+$0.16 (+3.02%)

अंतिम अपडेट: 26 मई 2026

प्राइस हिस्ट्री

हाल की खबरें

तृतीय-पक्ष स्रोतों द्वारा प्रदान की गई समाचार। वित्तीय सलाह नहीं है।

विश्लेषण

कंपनी का अवलोकन

Tilray Brands, Inc. operates as a lifestyle consumer products company dedicated to the research, cultivation, processing, and distribution of medical cannabis products across Canada, the United States, Europe, the Middle East, Africa, and international markets. The corporation functions within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical or therapeutic goods rather than mass-market over-the-counter medications. This entity employs a workforce of 2,842 individuals and holds a market capitalization of $786.70M, reflecting the total market value of all outstanding shares of its stock. With an annual revenue (TTM) of $858.28M, these valuation metrics indicate a company of significant scale that generates substantial top-line sales, yet the market cap relative to revenue suggests the market is pricing in high expectations for future profitability or facing challenges in converting current sales into shareholder value consistent with its sector peers.

वित्तीय स्वास्थ्य

The company reported a revenue of $858.28M for the trailing twelve months, yet it recorded a net income of $-1,344,620,032, a massive discrepancy that reveals a deeply distressed cost structure where expenses far exceed total sales generation. Despite generating $17.76M in EBITDA, the firm reported a free cash flow of $-31,062,250, indicating that capital expenditures and working capital requirements are consuming cash reserves faster than operations can replenish them. The gross margin stands at 27.7%, suggesting that for every dollar of sales, the company retains roughly 28 cents before operating expenses, while the operating margin of -52.7% and profit margin of -156.7% highlight severe operational inefficiencies or high fixed costs relative to the current revenue base. On the balance sheet, the company holds $425.66M in cash against $343.90M in debt, resulting in a debt-to-equity ratio of 63.61, which signifies a highly leveraged position where debt obligations are substantial relative to the equity base. The current ratio is 2.79, which indicates a robust short-term liquidity position capable of covering short-term liabilities nearly three times over with available current assets. Furthermore, the return on equity is -63.2% and the return on assets is -1.5%, metrics that reveal management has struggled to generate positive returns on shareholder capital or the asset base utilized to run the business.

मूल्यांकन आकलन

The valuation metrics present a complex picture with a P/E ratio (TTM) listed as N/A due to the negative earnings, while the forward P/E is 24.89, implying that the market is pricing the stock based on anticipated future profitability rather than current performance. The price-to-book ratio is 0.45, which indicates that the stock is trading at less than half its book value, suggesting the market may be discounting the company's assets significantly or anticipating substantial future impairment. Alternative valuation measures such as a price-to-sales ratio of 0.92 and an EV/EBITDA of 165.45 suggest that the stock is priced at a premium relative to its sales and earnings power, a valuation often seen in growth-oriented companies facing profitability hurdles. The stock's 52-week high was $23.20 and the 52-week low was $3.50, placing the current trading price in a range that reflects extreme volatility and a significant distance from recent peaks. The beta value of 2.11 indicates that the stock's price volatility is more than twice that of the broader market, meaning the asset experiences much larger swings in price for every 1% move in the overall market index.

Growth & Income

The revenue growth year-over-year is -7.8%, while earnings growth is N/A due to the negative net income, implying that the company is currently contracting in terms of sales and has failed to generate any earnings growth to speak of. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the entity retains all earnings or burns cash to fund operations and growth initiatives. The overall growth and income profile characterizes Tilray Brands, Inc. as a high-volatility, negative earnings stock with no current income generation for shareholders. The combination of negative revenue growth, severe losses, and a lack of dividend distribution suggests the company is in a transformational or distressed phase where capital preservation is not currently being prioritized over shareholder returns.

समकक्ष तुलना

Tilray Brands, Inc. (TLRY) दवा निर्माता - विशेष और जेनेरिक उद्योग में कार्यरत है। बाजार पूंजीकरण के आधार पर इसके निकटतम समकक्षों से तुलना इस प्रकार है:

कंपनी टिकर मार्केट कैप P/E अनुपात
Tilray Brands, Inc. TLRY $651.84M N/A
Takeda Pharmaceutical Company Limited TAK $50.14B 41.8
Haleon plc HLN $40.92B 18.5
Teva Pharmaceutical Industries Limited TEVA $40.30B 25.8

दवा निर्माता - विशेष और जेनेरिक उद्योग का औसत P/E अनुपात 47.5x है। Tilray Brands, Inc. का P/E अनुपात N/A है।

यह विश्लेषण AI द्वारा केवल सूचनात्मक उद्देश्यों के लिए तैयार किया गया है और यह वित्तीय सलाह नहीं है। डेटा में देरी या अशुद्धि हो सकती है। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और किसी योग्य वित्तीय सलाहकार से परामर्श लें।

Tilray Brands, Inc. के बारे में

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the company provides entertainment products. It offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Tilray Craft, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Tilray Medical, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Cruisies, Atwater Brewery, Hiball Energy, Liquid Love, Hop Valley Brewing, Redhook Brewery, Revolver Brewing, Square Mile Cider, Mock One, Widmer Brothers Brewing, Runner's High Brewing Company, SweetWater Brewing Company, Terrapin Beer Co., Happy Flower, Fizzy Jane's, Herb & Bloom, 420 Fizz, and Fresh Hemp Foods brands. The company sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.

कंपनी विवरण अंग्रेजी में दिखाया गया है।

वेबसाइट देखें →

मुख्य आंकड़े

मार्केट कैप
$651.84M
P/E अनुपात
N/A
52 सप्ताह उच्च
$23.20
52 सप्ताह निम्न
$3.50
औसत वॉल्यूम
4.57M
बीटा
1.94

डेटा yfinance के माध्यम से Yahoo Finance द्वारा प्रदान किया गया है। दैनिक अपडेट।

कंपनी जानकारी

एक्सचेंज
NASDAQ
देश
Canada
कर्मचारी
2,842